Cleantech Transit, Inc. (CLNO)
A major advantage of using biomass as a source of fuels or chemicals is its renewability. Utilizing sunlight energy in photosynthesis, plants metabolize atmospheric carbon dioxide to synthesize biomass.
Biomass energy is derived from five distinct energy sources: garbage, wood, waste, landfill gases, and alcohol fuels. Wood energy is derived both from direct use of harvested wood as a fuel and from wood waste streams. The largest source of energy from wood is pulping liquor or “black liquor,” a waste product from processes of the pulp, paper and paperboard industry. Waste energy is the second-largest source of biomass energy. The main contributors of waste energy are municipal solid waste (MSW), manufacturing waste, and landfill gas. Biomass alcohol fuel, or ethanol, is derived primarily from sugarcane and corn. It can be used directly as a fuel or as an additive to gasoline.
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could generate benefit the Company’s manufacturing clients worldwide.
Cleantech Transit Inc. recently announced that it has successfully signed a term sheet with Phoenix Energy (www.phoenixenergy.net), a manufacturer and distributor of biomass-generated power plants.
Under the terms of the agreement, Cleantech has an option to acquire a 25% interest into Phoenix Energy’s asset base, which includes a fully constructed, one-half megawatt (500 kilowatt) biomass energy project located in California. Phoenix Energy has developed an eco-friendly system that converts 100% recyclable agricultural and wood waste (biomass) into cleaner burning energy (heat, electricity) and other salable byproducts.
For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com
icad Inc. (Nasdaq:ICAD) announced that the Company will release financial results for the fourth quarter and fiscal year ended December 31, 2010, following the close of the market on Wednesday, March 23, 2011. Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern Time on Thursday, March 24, 2011 to discuss fourth quarter and full year 2010 financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-299-7635 (domestic) or 617-786-2901 (international) and entering passcode 52212023 a few minutes before 10:00 a.m. ET on Thursday, March 24, 2011. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.
iCAD, Inc. provides image analysis and workflow solutions that enable radiologists and other healthcare professionals to identify pathologies and pinpoint cancer earlier.
Superior Bancorp (Nasdaq:SUPR) announced that it has appointed C. Marvin Scott Chairman & CEO and Rick D. Gardner President of the company, subject to regulatory approval. These appointments are consistent with the company’s management succession plan and are being made in conjunction with the retirement of Superior Bancorp’s Chairman, President & CEO, C. Stanley Bailey, effective. Scott has served as Vice Chairman of the company and CEO of Superior Bank since October 2009 and, prior to that, as President, beginning in 2005. Over his 40 years of banking experience, Scott has served in senior leadership positions with Silver Acquisition Corp., Overland Park, KS., Superior Financial Corp., Little Rock, AR., Hancock Bank, Gulfport, MS., AmSouth Bank and Crestar Bank, Richmond, VA.
Superior Bancorp operates as the holding company for Superior Bank that provides various banking and related services to individual and corporate customers in Alabama and Florida.
Bionovo, Inc. (Nasdaq:BNVI) announced financial results for the year ended December 31, 2010. n 2010, the Company announced the following regarding Menerba�, its lead drug candidate for the treatment of menopausal hot flashes: In December, the Company received minutes from its successful meeting with the FDA in November, confirming agreements reached on the clinical development plan for Menerba. In September, an “End of Phase 2″ Type B meeting with the FDA resulted in a binding agreement on the Chemistry, Manufacturing and Control (CMC) plan for Menerba. In July, the Company received formal guidance from the European Medicines Agency (EMA), defining and approving a regulatory pathway to marketing approval for Menerba in Europe.
Bionovo, Inc., a clinical stage drug discovery and development company, focuses on women’s health and cancer primarily in the United States. Its lead drug candidate, Menerba, which completed a Phase II clinical trial, is a receptor sub-type selective estrogen receptor modulator for the treatment of vasomotor symptoms of menopause.
No comments:
Post a Comment